Global Custom Market Research Reports Provider Company

phone

Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review

  • Published Date: 29 Aug 2018
  • Number of Pages: 56
  • Category: SWOT Analysis
  • Country: India
Cipla Ltd (CIPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cipla Ltd (Cipla) is a global pharmaceutical company which manufactures and distributes branded formulations, generics and active pharmaceutical ingredients (APIs). It offers products for various therapeutic categories including cardiovascular, childrens health, dermatology and cosmetology, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, oncology, neurosciences, ophthalmology, respiratory, osteoporosis, urology and womens health. The company also operates in consumer healthcare and biosimilar businesses. Cipla is also involved in the manufacture of and metered-dose inhaler devices and spacers and related devices. The company offers its products in India, North America, South Africa and key regulated and emerging markets. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd Key Recent Developments

Jul 13,2018: Cipla to acquire South African drug developer Mirren
Jul 13,2018: Cipla Opens Up To Crowd Sourcing Innovation
Jun 26,2018: Consumers need to understand the risks associated with using medication to combat pain
Jun 12,2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda
May 22,2018: Cipla announces Q4 & FY18 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Cipla Ltd - Key Facts 6
Cipla Ltd - Key Employees 7
Cipla Ltd - Key Employee Biographies 8
Cipla Ltd - Key Operational Employees 9
Cipla Ltd - Major Products and Services 10
Cipla Ltd - History 11
Cipla Ltd - Company Statement 17
Cipla Ltd - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 Company Analysis 21
Company Overview 21
Cipla Ltd - Business Description 22
Business Segment: New Ventures 22
Overview 22
Performance 22
Business Segment: Pharmaceuticals 22
Overview 22
Performance 22
Geographical Segment: India 22
Performance 22
Geographical Segment: Rest of the World 22
Performance 22
Geographical Segment: South Africa 23
Performance 23
Geographical Segment: United States of America 23
Performance 23
R&D Overview 23
Cipla Ltd - Corporate Strategy 24
Cipla Ltd - SWOT Analysis 25
SWOT Analysis - Overview 25
Cipla Ltd - Strengths 25
Cipla Ltd - Weaknesses 26
Cipla Ltd - Opportunities 27
Cipla Ltd - Threats 28
Cipla Ltd - Key Competitors 29
Section 3 Company Financial Ratios 30
Financial Ratios - Capital Market Ratios 30
Financial Ratios - Annual Ratios 31
Performance Chart 34
Financial Performance 34
Financial Ratios - Interim Ratios 35
Financial Ratios - Ratio Charts 36
Section 4 Companys Lifesciences Financial Deals and Alliances 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38
Cipla Ltd, Recent Deals Summary 39
Section 5 Companys Recent Developments 40
Jul 13, 2018: Cipla to acquire South African drug developer Mirren 40
Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 41
Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 43
Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 44
May 22, 2018: Cipla announces Q4 & FY18 results 45
Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 46
Mar 26, 2018: Cipla Launches Authorized Generic Of Aloxi 47
Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 48
Aug 11, 2017: Cipla Announces Q1FY 18 Results 49
Jun 20, 2017: American Cancer Society and Clinton Health Access Initiative Announce Collaborations with Pfizer and Cipla to Increase Access to Lifesaving Cancer Treatment in Africa 50
Section 6 Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables


Cipla Ltd, Key Facts 6
Cipla Ltd, Key Employees 7
Cipla Ltd, Key Employee Biographies 8
Cipla Ltd, Key Operational Employees 9
Cipla Ltd, Major Products and Services 10
Cipla Ltd, History 11
Cipla Ltd, Subsidiaries 18
Cipla Ltd, Key Competitors 29
Cipla Ltd, Ratios based on current share price 30
Cipla Ltd, Annual Ratios 31
Cipla Ltd, Annual Ratios (Cont...1) 32
Cipla Ltd, Annual Ratios (Cont...2) 33
Cipla Ltd, Interim Ratios 35
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 38
Cipla Ltd, Recent Deals Summary 39
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55

List Of Figures


Cipla Ltd, Performance Chart (2014 - 2018) 34
Cipla Ltd, Ratio Charts 36
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 37
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 38

Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Leclanche SA (LECN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report

NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports